摘要
目的:动态监测慢性乙型肝炎患者接受恩替卡韦(entecavir,ETV)治疗过程中的乙型肝炎表面抗原(hepatitis B surface antigen,HBsAg)水平,探讨HBsAg水平对治疗效果的预测价值.方法:严格入选90例慢性乙型肝炎患者,进行1年的E T V治疗,于0、3、6、9、12 m o检测HBs Ag、乙型肝炎病毒(hepatitis B virus,HBV)DNA水平,采用t检验、Pearson相关性分析、受试者工作特征(receiver operating characteristic,ROC)曲线等进行分析.结果:52例(57.78%)患者经治疗后有效,38例(42.22%)无效,有效组年龄明显高于无效组,HBs Ag、HBV DNA水平明显低于无效组(P<0.05);有效组和无效组HBs Ag及HBV D N A水平均呈下降趋势,有效组下降速度明显快于无效组(P<0.05);HBs Ag和HBV DNA呈明显的正相关关系(r=0.5353,P<0.0001);各时点HBs Ag水平对ETV抗病毒治疗有效具有预测价值,ROC曲线下的面积从小到大依次为:治疗3 mo<基线<治疗6 mo<治疗9 mo<治疗12 mo.结论:慢性乙型肝炎患者血清HBs Ag水平,可以作为其抗病毒有效性的预测因子,其检测简单、经济、可靠,值得在临床上推广使用.
AIM： To dynamicly monitor serum hepatitis B surface antigen（HBs Ag） levels in chronic hepatitis B patients receiving entecavir（ETV） to explore whether serum HBsAg level can predict the therapeutic effect of an tiviral treatment.METHODS： Ninety chronic hepatitis B patients were selected strictly and given ETV for one year. HBs Ag and hepatitis B virus（HBV） DNA levels were determined at 0, 3, 6, 9, and 12 mo.The t-test, Pearson correlation, and receiver operating characteristic（ROC） curve were used for analysis. RESULTS： A total of 52（57.78%） patients showed a response to ETV treatment, and 38（42.22%） did not. Age was significantly greater in the response group than in the non-responsegroup, while HBs Ag and HBV DNA levels were significantly lower in the response group（P〈0.05）. HBs Ag and HBV DNA levels were decreased in both groups, and the decreases were more significant in the response group（P〈0.05）. HBs Ag levels were significantly correlated with HBV DNA levels（r = 0.5353, P〈0.0001）. The area under the ROC curve was lowest at 3 mo after treatment, followed by at baseline, at 6 mo, at 9 mo, and at 12 mo after treatment. CONCLUSION： Serum HBs Ag levels in patients with chronic hepatitis B can be used as a predictor of response to antiviral treatment.
出处
《世界华人消化杂志》
CAS
2015年第3期451-455,共5页
World Chinese Journal of Digestology
